Chimeric Antigen Receptor T-cell therapy (CAR-T) targeting CD19 has transformed the management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B-ALL), with FDA approval of tisagenlecleucel (tisa-cel) for pediatric/young adult patients and brexucabtagene autoleucel (brexu-cel) for adults. Efficacy is contingent upon several factors including disease burden. Emerging data suggests that bridging therapy, lymphodepletion and for some patients, consolidation therapy have an …